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Iron overload predisposes to diabetes, and higher ferritin levels have been associated with 
diabetes. However, it is unclear whether ferritin reflects differences in iron-related parameters 
between diabetic and non-diabetic persons. We examined associations of serum ferritin, iron 
and transferrin saturation with Type 2 diabetes in adults without genetic predisposition to iron 
overload. 
Design, participants and measurements 
Cross-sectional analysis of community-dwelling men and women aged 17-97 years from the 
Busselton Health Survey, Western Australia. Men and women carrying genotypes associated 
with haemochromatosis (C282Y/C282Y or C282Y/H63D) were excluded. Serum ferritin, 
iron and transferrin saturation were assayed. 
Results 
There were 1,834 men (122 with diabetes, 6.6%) and 2,351 women (141 with diabetes, 
6.0%). In men, higher serum ferritin was associated with diabetes after adjusting for age, 
smoking, alcohol, cardiovascular history, BMI, waist, blood pressure, lipids, CRP, 
adiponectin, ALT and GGT (odds ratio [OR]: 1.29 per 1 unit increase log ferritin, 95% 
confidence interval [CI]=1.01-1.65, p=0.043). In women, higher serum ferritin was 
associated with diabetes (fully-adjusted OR: 1.31 per 1 unit increase log ferritin, 95% 
CI=1.04-1.63, p=0.020; 1.84 for tertile (T)3 vs T1, 95% CI=1.09-3.11). Neither iron levels 
nor transferrin saturation were associated with diabetes risk in men or women. Higher ferritin 
was not associated with insulin resistance in non-diabetic adults. 
Conclusions 
In adults, higher ferritin levels are independently associated with prevalent diabetes while 
iron and transferrin saturation are not. Ferritin is a robust biomarker for diabetes risk, but 
4 
further investigation is needed to clarify whether this relationship is mediated via iron 
metabolism. 
Introduction 
Diabetes mellitus is a recognised complication of excessive iron accumulation due to 
increased absorption and retention of dietary iron in the setting of hereditary 
haemochromatosis, and transfusion-dependent iron overload [1,2]. Proposed underlying 
mechanisms include roles for iron accumulation in both beta cell failure and insulin 
resistance, with insulin resistance being more relevant to diabetes risk in the setting of 
transfusion or diet-related iron excess [2]. Serum ferritin levels are commonly utilised as a 
marker of body iron stores, and both dietary iron intake and higher ferritin levels predict 
incidence of Type 2 diabetes in epidiemological studies [3-5]. Conversely, iron restriction 
improves glycemia in diabetic rats [6] and phlebotomy reduces HbA1c levels in patients with 
Type 2 diabetes who have high ferritin levels [7]. However it remains unclear whether higher 
ferritin levels are a manifestation of excessive body iron stores which interfere directly with 
glucose metabolism; or represent a marker of systemic processes such as inflammation which 
correlate to diabetes risk [2]. 
In prospective studies, dietary iron intake in the form of heme from meat products and serum 
ferritin levels predict incidence of Type 2 diabetes but these associations are attenuated by 
adjustment for markers of inflammation [8]. Furthermore, there is doubt over whether a dose-
response effect exists with a non-linear association being reported in a recent meta-analysis 
[9]. Recently, iron has been found to negatively regulate adiponectin, an insulin-sensitising 
adipokine, suggesting that adiponectin may mediate the relationship between iron and 
glucose metabolism [10]. To clarify whether or not ferritin and other markers of iron 
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metabolism are associated independently with diabetes risk, we analysed the association of 
serum ferritin, iron and transferrin with diabetes risk with adjustment for conventional risk 
factors, the inflammatory marker C-reactive protein (CRP) and adiponectin in a large cohort 
of community-dwelling adult men and women. 
Participants and Methods 
Study population 
Busselton is a coastal town in Western Australia, whose residents have participated in a series 
of health surveys from 1966 onwards. In 1994-1995, all surviving subjects of earlier 
Busselton surveys were invited to participate in a follow-up survey [11]. More than 90% of 
the Busselton population is of Caucasian ethnic origin. The present study is based on 4,185 
men and women aged 19-97 years who attended the 1994/95 survey and provided blood 
samples for analysis. The study was approved by the Human Research Ethics Committee of 
the University of Western Australia, and all participants provided written informed consent.  
Assessment of medical comorbidities 
Methods used in the Busselton Health Survey have been described previously [11]. 
Participants were asked to complete a comprehensive health and lifestyle questionnaire and 
underwent a physical assessment. Blood pressure was measured using a mercury 
sphygmomanometer after five minutes at rest in a sitting position. Height was measured using 
a stadiometer and weight in light underclothes. Smoking, diabetes, and the use of 
antihypertensive or glucose-lowering medications were obtained via questionnaire. 
Participants were defined as having diabetes if they reported being told by a doctor that they 
had diabetes, and/or had a fasting blood glucose ≥7.0 mmol/L, or were taking glucose-
lowering medications. Participants were considered to have Type 2 diabetes unless they (i) 
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reported age of onset <40 years and were commenced on insulin at diagnosis, or (ii) had age 
of onset between 40-60 years, were commenced on insulin from the time of diagnosis, were 
on insulin at recruitment and had body mass index (BMI) <30 kg/m2 [12]. Other medical 
history was assessed from questionnaire responses and also via the Western Australian Data 
Linkage System (WADLS), which captures electronically all admissions to public or private 
hospitals in Western Australia [13]. A history of coronary heart disease (CHD) or stroke was 
defined as any hospital admission with a primary or secondary diagnosis of CHD or stroke 
during the preceding 15 years prior to the survey.  
Laboratory assays 
Blood samples were collected in the early morning after an overnight fast. Serum ferritin, 
iron and transferrin saturation, and mutations in the HFE gene were assessed as previously 
reported [14]. Briefly, serum ferritin levels were measured by chemiluminescence 
immunoassay (ACS-180, Chiron Diagnostics, Norwood, Massachusetts, USA). Serum iron 
levels were measured by a standard colorimetric method and serum transferrin levels by 
immunoturbidimetry on an automated analyser (Model 917, Hitachi, Toyko, Japan). Serum 
transferrin saturation values were calculated as follows: ([serum iron/2]*serum 
transferrin)*100. DNA was extracted from whole blood and PCR analysis performed to 
identify C282Y and H63D mutations of the HFE gene. Other biochemical analyses were 
performed as previously described [15]. Briefly, fasting serum cholesterol, HDL and 
triglycerides were determined at the time of the survey by standard enzymatic methods 
(Hitachi 747 analyser, Roche Diagnostics, Australia). Glucose was measured using a 
hexokinase assay. Insulin was assayed using a Tosoh A1A-600 immunoassay analyzer using 
a two-site immunoenzymometric assay. We measured C-reactive protein (CRP) using a 
particle-enhanced immunoturbidimetric assay on a Modular analyser (Roche Diagnostics, 
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Germany). Plasma adiponectin levels were measured by a commercially available 
quantitative sandwich enzyme immunoassay technique (R&D Systems Inc., Minneapolis, 
Minnesota, USA). We estimated insulin resistance using homeostatic models (HOMA-R) as 
previously described [16]. Adults with glucose ≤3.5 or >25 mmol/L were excluded. 
HOMA-R was calculated as (insulin*glucose)/22.5 and was log transformed for analyses. 
Statistical analyses 
Descriptive statistics are presented as mean and standard deviation (SD) or as percentages 
(Table 1). Logistic regression models were used to examine the relationships between serum 
ferritin, iron and transferrin saturation as continuous variables and categorised into tertiles 
with the presence of diabetes in men and women (Tables 2-4). Models were adjusted 
sequentially for variables that could potentially modify their association with prevalent 
diabetes. Models were age-adjusted, then additionally adjusted for smoking, alcohol 
consumption, CHD or stroke history, BMI, waist, systolic and diastolic blood pressure, high-
density lipoprotein cholesterol (HDL), triglycerides, CRP, adiponectin, alanine transaminase 
(ALT) and gamma-glutamyl transpeptidase (GGT). Variables were log transformed where 
the original distributions were skewed. To identify the important and independent correlates 
of (log) HOMA-R in non-diabetic men and women we fitted a multivariable model (Table 5). 
A p value of <0.05 or 95% confidence intervals that did not cross 1.0 were regarded as 
significant. 
Results 
Characteristics of the study population 
The age ranges for men and women were 16.9 to 97.3 and 16.5 to 92.2 years respectively.  
We excluded 22 adults with Type 1 diabetes and 69 who carried either of the C282Y/C282Y 
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or C282Y/H63D genotypes associated with hereditary haemochromatosis. This left 1,834 
men (122 with Type 2 diabetes, 6.6%) and 2,351 women (141 with Type 2 diabetes, 6.0%) 
for analysis. Characteristics of the study cohort stratified by gender and the presence or 
absence of diabetes are shown (Table 1). Serum ferritin, iron and transferrin saturation are 
shown without and with log transformation and as tertiles. Men with diabetes were older, 
more likely to have smoked and less likely to be current drinkers. In men, diabetes was 
associated with a history of cardiovascular disease, higher BMI and waist circumference, 
systolic and diastolic blood pressure, triglycerides, fasting glucose, insulin, HOMA-R, GGT 
and CRP, but with lower HDL. These cardiometabolic variables were similarly associated 
with diabetes in women with the exceptions of smoking and diastolic blood pressure, as was 
menopausal status. Ferritin levels were significantly higher in men and women with diabetes, 
when examined as both continuous variables and in tertiles. Serum iron was not associated 
with diabetes in either men or women. Lower transferrin saturation was associated with 
diabetes when analysed as a log transformed variable or in tertiles in men but not in women. 
TABLE 1 
Association of ferritin with prevalent diabetes 
In men, ferritin was significantly associated with diabetes when examined as a continuous 
variable and in tertile groups after adjustment for age alone (Table 2). The association of 
ferritin as a continuous variable with diabetes remained significant in further models that 
adjusted for all other cardiometabolic risk factors including CRP, adiponectin, ALT and GGT 
with an odds ratio (OR) of 1.29 per 1 unit increase log ferritin (95% confidence interval 
[CI]=1.01-1.65). In women, there was also a significant association between ferritin and 
diabetes (Table 2). The fully-adjusted OR for diabetes was 1.31 per 1 unit increase log 
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ferritin (95% CI=1.04-1.63); and 1.84 (95% CI=1.09-3.11) for women with ferritin in the 
highest tertile (T3) of values compared to the lowest (T1). 
TABLE 2 
Regression analysis of serum iron and prevalent diabetes 
In men and women, serum iron was not significantly associated with diabetes when 
examined either as a continuous variable or in tertile groups. The fully-adjusted OR for men 
was 0.90 (95% CI=0.47-1.72) for a 1 unit increase in log ferritin and 0.80 (95% 
CI=0.49-1.33) for T3 vs T1. For women the fully-adjusted OR were 1.08 (95% 
CI=0.64-1.83) and 1.21 (95% CI=0.73-1.99) respectively. 
Regression analysis of transferrin saturation and prevalent diabetes 
Of the 1,834 men and 2,351 women analysed, there were 57 men (6 diabetic and 51 non-
diabetic) and 29 women (1 diabetic and 28 non-diabetic) with transferrin saturation >50%. In 
men, there was some evidence of a negative association between transferrin saturation and 
diabetes after adjustment for age alone. The age-adjusted OR of diabetes was 0.51 (95% 
CI=0.31-0.84, p=0.029 for between groups comparison) for transferrin saturation in T3 vs T1, 
but this was attenuated to 0.57 (95% CI=0.34-0.96, p=0.108 for between groups comparison) 
after full adjustment for other risk factors. Transferrin saturation as a continuous variable was 
not associated with diabetes in men (fully-adjusted OR 0.83, 95% CI=0.49-1.43). In women, 
there was no significant association of transferrin saturation with prevalent diabetes (fully-
adjusted OR 1.11, 95% CI=0.71-1.74 for continuous variable and 1.26, 95% CI=0.80-1.99 for 
T3 vs T1).  
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Multivariable analysis of factors associated with insulin resistance 
The fitted multivariable model examining factors associated with insulin resistance as 
estimated using HOMA-R is shown for men and women without diabetes (Table 5). In 
men, age was negatively associated with HOMA-R, as were HDL. CHD or stroke history, 
BMI, waist circumference, systolic blood pressure, triglycerides, CRP and ALT were 
positively associated with HOMA-R in men. In women, age, use of hormone replacement 
therapy in post-menopausal women, and HDL were negatively associated with HOMA-R. 
BMI, waist circumference, systolic blood pressure, triglycerides and GGT were positively 
associated. Adiponectin was inversely associated with HOMA-R in both men and women. 
Ferritin was not associated with HOMA-R in either men or women without diabetes. 
TABLE 5 
Discussion 
Higher serum ferritin levels are independently associated with diabetes in men and women, 
both in age-adjusted and in multivariable adjusted models accounting for cardiometabolic 
factors. This association is present for ferritin analysed as a continuous variable, and in 
women for ferritin levels in the highest tertile of values. However neither serum iron nor 
transferrin saturation were associated with diabetes in this cohort. Furthermore, ferritin 
was not associated with insulin resistance in men or women without diabetes. 
Our results are consistent with previous studies relating serum ferritin levels to diabetes 
risk [3-5,17-19]. However, higher ferritin levels are also associated with obesity and the 
metabolic syndrome [20,21] and with cardiovascular risk [22]. There is also a recognised 
association between ferritin levels and the presence and severity of fatty liver disease [23]. 
11 
We found that the association of serum ferritin with prevalent diabetes was largely 
unchanged after adjustment for cardiometabolic risk factors including adiponectin, and it 
remained significant after adjustment for ALT and GGT. Therefore, our results suggest that 
the relationship between ferritin level and diabetes risk is not modulated by the presence of 
obesity or by common risk factors for cardiovascular disease and diabetes. Furthermore, in 
our analysis ferritin was not independently associated with insulin resistance as assessed 
using HOMA-R in men or women without diabetes. This contrasts with previous reports 
implicating ferritin levels with insulin resistance syndromes and with hyperinsulinaemia 
[20,21,24,25]. Therefore, while the association between higher ferritin and diabetes is 
robust, the mechanisms by which ferritin might contribute to diabetes risk remains unclear. 
We measured serum iron and transferrin saturation to provide additional indicators of body 
iron stores [26]. Transferrin serves as the major vehicle for iron delivery into cells via the 
transferrin receptor, with increased saturation reflective of higher body iron stores [26]. 
Previous studies have indicated that transferrin saturation ≥50% is associated with increased 
risk of diabetes [27,28]. However, we found no association of either serum iron or transferrin 
saturation with diabetes in men or women, with the large majority of our study participants 
having transferrin saturation below this threshold. By contrast, there was a trend for higher 
transferrin saturation to be associated with lower risk of diabetes in men, although this was 
not significant in the fully adjusted models. Nevertheless, the trend is in the opposite 
direction from that expected should higher body iron stores contribute to diabetes risk. We 
found no evidence to support the concept that iron availability as reflected by serum iron or 
transferrin saturation contributes to diabetes risk. Previous epidemiological studies have 
shown associations of not only ferritin levels [3-5] but also dietary heme iron intake with risk 
of Type 2 diabetes [3,8,9]. We did not have data on dietary intake in our cohort however our 
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examination of iron status included serum iron and transferrin saturation in addition to 
ferritin. The discordance between associations of ferritin with Type 2 diabetes and the 
absence of any association of serum iron or transferrin saturation are consistent with ferritin 
being a marker of metabolic risk distinct from iron metabolism.    
In addition to being an indicator of body iron stores, circulating ferritin is an acute phase 
reactant which like CRP is elevated in inflammatory conditions, while transferrin is not [29]. 
Inflammation is a mediator of diabetes risk and higher levels of CRP are associated with 
impaired glucose tolerance and diabetes [30,31]. Adiponectin is has also been proposed as a 
mediator of inflammatory responses and insulin sensitivity [32]. However, adjustment for 
CRP and for adiponectin in the final multivariate model did not alter the association of 
ferritin with diabetes in men and women. Therefore, measurement of ferritin captures a key 
determinant of diabetes risk that is not achieved via measurement of either CRP, adiponectin 
or both. Ferritin is a robust biomarker for diabetes in our study population, but the negative 
associations of iron and transferrin saturation with diabetes lead us to postulate that 
mechanisms independent of body iron status are involved. 
Strengths of our study are the large size of the cohort, its inclusion of men and women 
spanning younger, middle and older ages, extensive phenotyping and availability of physical, 
metabolic and laboratory variables for the analyses. As this cohort had previously been 
studied to evaluate the clinical expression of hereditary haemochromatosis [14], genotyping 
data were available and we were able to exclude men and women with C282Y and H63D 
polymorphisms associated with this disease. We compared associations not only of ferritin 
but also serum iron and transferrin saturation, we conducted analyses adjusting for a wide 
range of potential confounders and explored the influence of CRP and adiponectin. We 
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acknowledge several limitations of this study. This is an observational study and we 
performed a cross-sectional analysis thus we cannot infer causation. The men and women 
were community-dwelling survivors from previous surveys, thus a “healthy survivor” effect 
might be present. We did not have serial blood samples to assess longitudinal changes in the 
levels of ferritin, iron and transferrin instead we used a single blood sample albeit collected 
early in the morning in the fasted state. While HOMA-R is a useful tool for epidiemiological 
studies, it may not estimate insulin resistance as accurately as more invasive methods [16]. 
Additionally the Busselton cohort is almost entirely Caucasian in ethnicity thus care must be 
taken before extrapolating our findings to other populations. All participants in the study 
were community-dwelling adults who volunteered to attend a study centre for assessment, 
making it less likely that they were unwell with intercurrent illness at the time of blood 
sampling. 
Smaller studies have reported associations of higher ferritin with HOMA-R and with 
metabolic syndrome in both men and women [21,25,33]. One study of non-diabetic adults 
comprising 140 men and 277 women showed a correlation between ferritin level and HOMA-
R in women but not in men [34]. Given the size of our study population and the coefficients 
demonstrated, any clinically or statistically significant influence of ferritin on HOMA-R in 
men is unlikely to be present. There was no statistically significant association of ferritin with 
HOMA-R in women in our cohort. 
There are limited data documenting effects of venesection on diabetes risk. One study of 28 
patients with Type 2 diabetes reported improved insulin sensitivity and lower HbA1c after 
venesection [7]. Another in 64 adults with metabolic syndrome showed no difference in 
HOMA-R in control and phlebotomy groups [35]. Therefore additional studies are needed to 
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test whether manipulation of ferritin levels whether by phlebotomy, iron chelation therapy or 
dietary iron restriction would improve glucose metabolism. Putative mechanisms include 
reduction in cellular iron levels influencing enzymatic reactions in which iron is a cofactor, 
to changes in inflammation, cytokine profiles or other metabolic effects [1,2]. However, it 
remains plausible that mild to moderate elevation of ferritin in the context of Type 2 diabetes 
reflects underlying inflammation. Our results suggest that in future studies, consideration 
should be given to assessing both iron-dependent and independent pathways by which 
reduction of ferritin levels could ameliorate the risk of diabetes. 
Conclusions 
In summary, serum ferritin levels are a robust biomarker for diabetes risk in men and women. 
The association of higher serum ferritin levels with diabetes is not attributable to presence of 
cardiometabolic risk factors or inflammatory markers such as CRP. However, the absence of 
parallel associations of serum iron or transferrin saturation with diabetes in the same cohort 
suggests that ferritin captures influences beyond iron availability which contribute to diabetes 
risk. 
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Table 1: Characteristics of the study cohort stratified according to gender and absence or 
presence of diabetes mellitus. P-value is for the comparison of characteristic between diabetic 
and non-diabetic participants within each gender. 
 





















       
Diabetes duration (years)  8.4 (8.7)   10.8 (11.2)  
Diabetes treatment       
  Diet (%)  55.2   63.2  
  Tablets (%)  44.8   33.7  
  Insulin (%)  0.0   3.1  
       
Age (years) 49.8±17.0 65.3±11.3 <0.001 50.7±17.0 59.5±16.3 <0.001 
Smoking   <0.001   0.190 
  Never (%) 43.0 32.0  60.6 68.1  
  Ex (%) 40.5 60.7  28.3 24.1  
  Current (%) 16.4 7.4  11.0 7.8  
Drinking   0.002   <0.001 
  Non (%) 3.9 2.5  8.0 15.6  
  Ex (%) 6.4 14.8  10.7 17.0  
  Light (%) 48.7 43.4  69.2 56.7  
  Moderate/Heavy (%) 38.1 33.6  7.9 4.3  
  Unknown (%) 2.8 5.7  4.2 6.4  
Menopause status      <0.001 
  Pre/OC No (%)    35.5 26.2  
  Pre/OC Yes (%)    12.9 4.3  
  Post/HRT No (%)    36.2 52.5  
  Post/HRT Yes (%)    15.4 17.0  
CHD or stroke history (%) 7.2 23.8 <0.001 3.0 7.8 0.002 
BMI (kg/m2) 26.4 (3.4) 28.0 (3.5) <0.001 25.5 (4.5) 28.6 (5.7) <0.001 
Waist circumference (cm) 92.5 (10.2) 100.0 (9.7) <0.001 80.1 (11.3) 89.3 (13.5) <0.001 
SBP (mmHg) 126 (15) 138 (19) <0.001 122 (19) 130 (21) <0.001 
DBP (mmHg) 77 (10) 80 (11) 0.003 73 (10) 74 (10) 0.090 
HDL (mmol/L) 1.22 (0.31) 1.07 (0.28) <0.001 1.55 (0.38) 1.40 (0.43) <0.001 
Triglycerides (mmol/L) 1.42 (1.04) 1.91 (1.18) <0.001 1.16 (0.69) 1.66 (1.18) <0.001 
log Triglycerides 0.18 (0.56) 0.50 (0.53) <0.001 0.01 (0.51) 0.31 (0.62) <0.001 
Glucose (mmol/L) 4.89 (0.54) 7.32 (2.70) <0.001 4.73 (0.51) 6.94 (3.36) <0.001 
log Glucose (mmol/L) 1.58 (0.11) 1.94 (0.32) <0.001 1.55 (0.11) 1.86 (0.37) <0.001 
Insulin (mU/L) 7.10 (5.01) 11.5 (7.91) <0.001 6.71 (4.16) 14.8 (23.7) <0.001 
log Insulin (mU/L) 1.79 (0.57) 2.25 (0.62) <0.001 1.76 (0.53) 2.28 (0.83) <0.001 
Adiponectin (mg/L) 7.75 (5.30) 7.68 (5.76) 0.887 13.3 (8.0) 11.4 (7.3) 0.007 
log Adiponectin 1.84 (0.65) 1.80 (0.70) 0.426 2.41 (0.63) 2.25 (0.64) 0.003 
HOMA-R 1.58 (1.23) 3.86 (3.21) <0.001 1.44 (0.99) 4.97 (7.93) <0.001 
log HOMA-R 0.26 (0.61) 1.07 (0.75) <0.001 0.19 (0.57) 1.02 (1.04) <0.001 
CRP (mg/L) 2.61 (6.96) 4.35 (5.37) 0.007 3.41 (9.29) 4.97 (6.69) 0.058 
log CRP 0.21 (1.21) 0.91 (1.10) <0.001 0.47 (1.23) 0.96 (1.24) <0.001 
ALT (U/L) 27.4 (16.3) 29.7 (18.6) 0.129 18.9 (14.8) 21.8 (10.5) 0.019 
log ALT 3.19 (0.46) 3.25 (0.51) 0.173 2.83 (0.41) 2.99 (0.43) <0.001 
GGT (U/L) 30.2 (26.0) 42.7 (41.3) <0.001 20.7 (16.0) 31.8 (28.7) <0.001 
log GGT 3.24 (0.52) 3.50 (0.64) <0.001 2.89 (0.48) 3.21 (0.65) <0.001 
       
Ferritin (ng/mL) 208 (199) 296 (490) <0.001 86 (96) 118 (92) <0.001 
log Ferritin 5.05 (0.80) 5.27 (0.88) 0.004 4.05 (0.95) 4.43 (0.91) <0.001 
Ferritin group*   0.017   <0.001 
  1 (%) 33.6 27.9  33.9 19.9  
  2 (%) 33.9 27.0  33.8 28.4  
  3 (%) 32.5 45.1  32.2 51.8  
Iron (µmol/l) 19.0 (5.7) 18.4 (6.3) 0.289 17.3 (6.0) 16.5 (5.1) 0.153 
log Iron 2.90 (0.31) 2.86 (0.34) 0.169 2.78 (0.39) 2.75 (0.35) 0.339 
Iron group*   0.204   0.081 
  1 (%) 35.9 41.8  33.6 31.9  
  2 (%) 28.4 30.3  35.3 44.0  
  3 (%) 35.6 27.9  31.1 24.1  
Transferrin saturation (%) 29.7 (10.1) 28.4 (12.2) 0.165 25.4 (13.3) 24.2 (8.5) 0.310 
log Transferrin saturation 3.33 (0.35) 3.27 (0.40) 0.042 3.14 (0.44) 3.11 (0.43) 0.411 
Transferrin saturation group*   0.009   0.788 
  1 (%) 32.4 44.3  32.7 34.8  
  2 (%) 33.9 33.6  34.2 34.8  
  3 (%) 33.6 22.1  33.2 30.5  
       
* Men:  1 = Ferritin < 126 2 = 126 ≤ Ferritin < 233 3 = Ferritin ≥ 233 
    1 = Iron < 17   2 = 17 ≤ Iron < 21   3 = Iron ≥ 21 
    1 = TS < 25   2 = 25 ≤ TS < 33    3 = TS ≥ 33 
 Women: 1 = Ferritin ≤ 41  2 = 41 < Ferritin < 92  3 = Ferritin ≥ 92 
    1 = Iron < 15   2 = 15 ≤ Iron < 20   3 = Iron ≥ 20 
    1 = TS < 21   2 = 21 ≤ TS < 29    3 = TS ≥ 29 
 
